Search the Newsreel

Franchise Equity Partners Marks 50-Location Milestone with Velocity Auto Care Expansion

Achievement reflects continued expansion following 2024 acquisition, with 18 additional service centers planned through 2027 NEW YORK, Aug. 5, 2026 /PRNewswire/ -- Franchise Equity Partners (FEP), a private investment firm on a mission to create long-term partnerships with quality franchisees and franchisors, today announced …

Valvoline (NYSE:VVV) Posts Earnings Results, Beats Estimates By $0.07 EPS

Alvotech (ALVO) Could Be 72% Undervalued Following FDA Inspection Closure

Alvotech (ALVO) stock is under focus after the FDA closed its May 2026 inspection with a Voluntary Action Indicated classification, leading to a recent 23.87% share price return over 7 days despite a year-to-date decline. Analysts suggest the stock is 72.2% undervalued, with a …

Valvoline Inc reports results for the quarter ended June 30 - Earnings Summary

Valvoline Inc has released its earnings summary for the quarter that ended on June 30. The full article provides detailed financial results for the company during this period.

Valvoline (NYSE:VVV) Updates FY 2026 Earnings Guidance

Valvoline (VVV) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates

For the quarter ended June 2026, Valvoline (VVV) reported revenue of $544.6 million, up 24.1% over the same period last year. EPS came in at $0.57, compared to $0.47 in the year-ago quarter. The reported revenue represents a surprise of +1.49% over the Zacks …

Is Valvoline Inc (VVV) Undervalued After Q3 Earnings Beat? EPS: $0.51, Revenue: $544.6M, GF Score: 93/100

Valvoline (VVV) Q3 Earnings and Revenues Surpass Estimates

Valvoline (VVV) came out with quarterly earnings of $0.57 per share, beating the Zacks Consensus Estimate of $0.5 per share. This compares to earnings of $0.47 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings …

Valvoline beats Q3 estimates, raises guidance midpoints

Valvoline Inc. reported strong third-quarter results, exceeding analyst expectations for both adjusted earnings per share and revenue. The company achieved 8.0% system-wide same-store sales growth and raised its full-year fiscal 2026 revenue and same-store sales guidance, while its adjusted EPS midpoint guidance came in …

Palvella Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference

Palvella Therapeutics, Inc. (Nasdaq: PVLA) announced that its Founder and CEO, Wes Kaupinen, will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference on August 12, 2026. The company is a clinical-stage biopharmaceutical firm focused on developing novel therapies for …

Palvella Therapeutics: Q2 Earnings Snapshot

Palvella Therapeutics, Inc. (PVLA) reported a Q2 loss of $21.9 million, or $1.52 per share, missing Wall Street expectations. Analysts surveyed by Zacks Investment Research had estimated a loss of $1.16 per share for the Wayne, Pennsylvania-based company. The financial data was generated by …

Earnings Flash (VVV) Valvoline Inc. Reports Q3 Revenue $544.6M, vs. FactSet Est of $543.2M

Valvoline Inc. reported its Q3 revenue of $544.6 million, surpassing FactSet's estimate of $543.2 million. The company, which specializes in automotive preventive maintenance services, also updated its fiscal year 2026 outlook. This financial update follows other recent news, including adjusted earnings and revenue increases …

Valvoline adds 47 net stores as system-wide sales reach $1.05B

Valvoline faces earnings test as base oil shortage reshapes market By Investing.com

Valvoline Inc. is set to report its fiscal third-quarter earnings, with analysts anticipating strong growth despite an industry-wide base oil shortage. The company is expected to leverage this supply disruption to accelerate market share gains, driven by rising wholesale motor oil prices and strategic …

Palvella Therapeutics, Inc. - Common Stock (PVLA) Stock Price, News, Quote & History

This article provides comprehensive information on Palvella Therapeutics, Inc. (PVLA) stock, including its current price, historical data, and a compilation of recent news and press releases. Key updates include the company's progress on its New Drug Application (NDA) for QTORIN rapamycin for microcystic lymphatic …

Boston Partners (VVV) reports 5.17% beneficial stake in Valvoline common stock

Boston Partners has disclosed a 5.17% beneficial ownership stake in Valvoline Inc. common stock, totaling 6,597,960 shares as of June 30, 2026. The firm holds sole voting power over 6,227,151 shares and sole dispositive power over all 6,597,960 shares, primarily for discretionary client accounts. …

Palvella Therapeutics (NASDAQ:PVLA) Posts Quarterly Earnings Results, Misses Expectations By $0.35 EPS

Palvella Therapeutics, Inc. (PVLA) Q2 FY2026 earnings call transcript

Earnings Flash (PVLA) Palvella Therapeutics Posts Q2 Net Loss $1.52 a Share, vs. FactSet Est of $1.07 Loss

Palvella Therapeutics (PVLA) reported a Q2 net loss of $1.52 per share, which is wider than the FactSet estimate of a $1.07 loss. The company is a clinical-stage biopharmaceutical firm focused on rare genetic skin diseases, with its lead product candidate QTORIN rapamycin currently …

Palvella Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Palvella Therapeutics reported its second quarter 2026 financial results, highlighting significant progress in its clinical programs. Key updates include the submission of the first module of the rolling NDA for QTORIN™ rapamycin for microcystic lymphatic malformations, with a planned commercial launch in early 2027 …

Pacer Advisors Inc. Has $29.86 Million Holdings in Autoliv, Inc. $ALV

Pacer Advisors Inc. significantly increased its stake in Autoliv, Inc. (NYSE:ALV) by 3,296.4% in the first quarter, now holding 283,973 shares valued at $29.86 million, representing about 0.38% of the company. Autoliv maintains a "Moderate Buy" consensus rating from analysts with an average price …

ALVO|Alvotech SA|Price:3.785|Chg%:-0.335

Alvotech SA (ALVO) has a relatively weak fundamental profile but high growth potential, with its valuation considered fairly valued within the Biotechnology & Medical Research industry. Institutional ownership is very high, and analysts have recently rated it as a "Buy" with a target price …

Palvella Therapeutics (PVLA) Earnings Date and Reports 2026

Jennison Associates (PVLA) reports 960,619-share, 6.7% position in Palvella Therapeutics

Jennison Associates LLC has reported a 6.7% beneficial ownership stake in Palvella Therapeutics Inc., holding 960,619 shares of common stock as of June 30, 2026. The filing indicates Jennison has sole voting power and shared dispositive power over these shares. This disclosure, made via …

Novo misses, AstraZeneca holds steady, Alvotech clears FDA – the Nordic Pulse | 2026:31

This article provides the Nordic Life Science Weekly Report for Week 31, 2026, offering key insights into the market, major events, financial impact, development and research, and a catalyst watch. It highlights that Novo Nordisk missed expectations, AstraZeneca remained stable, and Alvotech received FDA …

Suze Orman says planning to work until 65 is a risky strategy — her 2 tips to help you retire when you want

Taylor Hill/Getty Images Moneywise and Yahoo Finance LLC may earn commission or revenue through links in the content below. Choosing to retire early is a far-off dream for many hard-working Americans. In fact, it's more like a fantasy for the one in two who …

AlTi Global (ALTI) Expected to Announce Quarterly Earnings on Monday

Alvo Minerals Boosts Brazilian Critical Minerals Push with Touro Drilling and Government-Backed Survey

Price to earnings forward of Valvoline, Inc. – BX:0V4

This page from TradingView provides financial information for Valvoline, Inc. (BX:0V4), specifically focusing on its forward price-to-earnings ratio. The content indicates that the market is currently closed with no trades recorded.

Allianz-Aktie Prognose: Sollten Sie jetzt kaufen?

Enterprise value to EBIT forward of Valvoline, Inc. – BX:0V4

This article displays the "Enterprise value to EBIT forward" metric for Valvoline, Inc. (BX:0V4) on the TradingView platform. It shows that the market for this stock is currently closed with no trades. The primary content is a single data point within a financial overview.

Allianz (XTRA:ALV) Holds A Growth Narrative, Is The Stock Overvalued?

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Allianz stock performance snapshot after recent trading session Allianz (XTRA:ALV) recently closed at €432.50, giving the insurer a market value of about €162.6b. The …

Alvotech (ALVO) Is Up 34.6% After FDA Clears Reykjavik Plant And BLAs Advance - Has The Bull Case Changed?

Alvotech (ALVO) stock rose 34.6% after the FDA cleared its Reykjavik manufacturing plant with a Voluntary Action Indicated classification, addressing previous observations and allowing the company to advance multiple Biologics License Applications (BLAs) in the US. This regulatory progress, along with the acceptance of …

Enterprise value to EBITDA forward of Palvella Therapeutics, Inc. – NASDAQ:PVLA

This article provides the enterprise value to EBITDA forward for Palvella Therapeutics, Inc. (NASDAQ: PVLA). It appears to be a financial data point presented within the TradingView platform, focused on the biotechnology sector. The content primarily lists navigation and footer elements of the TradingView …

Palvella Therapeutics, Inc. $PVLA Shares Bought by Avidity Partners Management LP

XS259833213 Bond Profile — Key Metrics

This article provides key metrics for the Autoliv, Inc. 4.25% 15-MAR-2028 bond, identified by XS259833213, traded on the Munich Stock Exchange. It details the issuer, issue and maturity dates, outstanding amount, face value, minimum denomination, and coupon rate. Autoliv, Inc. is described as a …